Martine Rothblatt, United Therapeutics CEO (Jack Plunkett/AP Images)
October 1, 2021 10:24 AM EDTUpdated 02:23 PM
Pharma

Unit­ed Ther­a­peu­tics tran­si­tions to pub­lic ben­e­fit cor­po­ra­tion more than 20+ years af­ter IPO

Max Gelman

Senior Editor

Unit­ed Ther­a­peu­tics has been a pub­lic com­pa­ny since 1999, but late Thurs­day the com­pa­ny an­nounced it’s en­ter­ing a new phase.

Unit­ed will be­come a pub­lic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times